ICOS ELISA kit (Human)

SKU: SEA777Hu

Size: 96Tests

# of Times Cited in literature: 6

Prepare Time: 1-3 days(please inquire for mutiple units)

Target Name: ICOS

Target Full Name: Inducible T-Cell Co Stimulator

Alternative Names: CD278; AILIM; Inducible T-Cell Costimulator; Activation-Inducible Lymphocyte Immunomediatory Molecule

Target Species: Human

Uniprot: Q9Y6W8

Gene ID: 29851

Featured Series: SE kit

Featured Series Function: Detects protein (regular version)

Specificity: Reactive with Human ICOS / Inducible T-Cell Co Stimulator

Method: Colormetric

Detection principle: Double-antibody Sandwich

Detection range: 15.6-1,000pg/mL

Sensitivity: 6.2pg/mL

Assay Time: 3h

Sample Size: 100uL

Recommended/Predicted Sample Types: Serum, Plasma, Urine, Cell Lysates and other Biological Fluids

Assay Precision: Intra-Assay: CV<10%, Inter-Assay: CV<12%

Reproducibility test menthod: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Inducible T-Cell Co Stimulator (ICOS) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Inducible T-Cell Co Stimulator (ICOS) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100

Storage: 4°C for 1 month/ -20°C for long-term(One year within shelf life)

Shelf-life: 12 months

Specificity: This assay has high sensitivity and excellent specificity for detection of Inducible T-Cell Co Stimulator (ICOS). No significant cross-reactivity or interference between Inducible T-Cell Co Stimulator (ICOS) and analogues was observed.

Stability: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary: 1. Prepare all reagents, samples and standards; 2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C; 3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C; 4. Aspirate and wash 3 times; 5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C; 6. Aspirate and wash 5 times; 7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C; 8. Add 50µL Stop Solution. Read at 450nm immediately.

Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Inducible T-Cell Co Stimulator (ICOS). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Inducible T-Cell Co Stimulator (ICOS). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Inducible T-Cell Co Stimulator (ICOS), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Inducible T-Cell Co Stimulator (ICOS) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Research Area: Signal transduction;Tumor immunity;Infection immunity;Immune molecule;

References Citing This Product: Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis

Effect of soluble inducible costimulator level and its polymorphisms on age-related macular degeneration.

Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis

Inducible T‐cell co‐stimulator (ICOS) and ICOS ligand are novel players in the multiple‐myeloma microenvironment

Increased Levels of ICOS and ICOSL Are Associated to Pulmonary Arterial Hypertension in Patients Affected by Connective Tissue Diseases